Pardes Biosciences, Inc. PRDS
We take great care to ensure that the data presented and summarized in this overview for PARDES BIOSCIENCES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PRDS
Top Purchases
Top Sells
About PRDS
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Insider Transactions at PRDS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 31
2023
|
James B. Tananbaum President and CEO |
BUY
Other acquisition or disposition
|
Indirect |
1,000
+50.0%
|
-
|
|
Aug 31
2023
|
James B. Tananbaum President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
16,813,146
-100.0%
|
-
|
|
Aug 31
2023
|
Michael David Varney Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
70,390
-100.0%
|
-
|
|
Aug 31
2023
|
Thomas G Wiggans Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
50,000
-100.0%
|
-
|
|
Aug 31
2023
|
J Jay Lobell Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
1,163,861
-100.0%
|
-
|
|
Aug 31
2023
|
J Jay Lobell Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
200,000
-100.0%
|
-
|
|
Aug 31
2023
|
Uri A Lopatin Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
351,948
-100.0%
|
-
|
|
Aug 31
2023
|
Uri A Lopatin Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,327,798
-100.0%
|
-
|
|
Aug 31
2023
|
Heidi Henson Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
316,753
-100.0%
|
-
|
|
Aug 31
2023
|
Elizabeth H. Lacy General Counsel, Secretary |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
211,169
-100.0%
|
-
|
|
Aug 31
2023
|
Mark Auerbach Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
70,390
-100.0%
|
-
|
|
Apr 05
2023
|
Foresite Capital Management V, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
773,952
+5.39%
|
$773,952
$1.5 P/Share
|
|
Apr 05
2023
|
Foresite Capital Opportunity Management V, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
773,952
+8.11%
|
$773,952
$1.5 P/Share
|
|
Dec 08
2022
|
Sean P. Brusky Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
21,000
+50.0%
|
$21,000
$1.19 P/Share
|
|
Dec 05
2022
|
Thomas G Wiggans Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
12,500
+20.0%
|
$12,500
$1.09 P/Share
|
|
Dec 02
2022
|
Thomas G Wiggans Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
12,500
+25.0%
|
$12,500
$1.07 P/Share
|
|
Dec 01
2022
|
Thomas G Wiggans Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$25,000
$1.04 P/Share
|
|
Dec 01
2022
|
Foresite Capital Management V, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
637,420
+4.74%
|
$0
$0.85 P/Share
|
|
Jul 19
2022
|
J Jay Lobell Director |
BUY
Other acquisition or disposition
|
Indirect |
1,163,861
+50.0%
|
-
|
|
Jul 19
2022
|
J Jay Lobell Director |
BUY
Other acquisition or disposition
|
Direct |
200,000
+50.0%
|
-
|
Last 12 Months Summary
| Other acquisition or disposition | 1K shares |
|---|
| Disposition due to a tender of shares in a change of control transaction | 7.76M shares |
|---|---|
| Sale (or disposition) back to the issuer | 16.8M shares |